Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR1 | P47211 | 7/20 | 0.52 |
| ▸ | GALR2 | O43603 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231983 | 0.84 | SMN1; SMN2 (0.58) | GALR1GALR2SMN1; SMN2BCL6 | |
| SCHEMBL5029097 | 0.83 | AGPAT2 (0.53) | GALR1GALR2PIK3CAAGPAT2ABCB1 | |
| SCHEMBL4838923 | 0.82 | GALR1 (0.67) | GALR1GALR2CDK1CDK4CCNB1 | |
| SCHEMBL27628522 | 0.81 | GALR1 (0.47) | GALR1GALR2CDK1CDK4CCNB1 | |
| SCHEMBL5550587 | 0.81 | GALR1 (0.48) | GALR1GALR2CDK1CDK4CCNB1 | |
| SCHEMBL4835239 | 0.78 | BCL6 (0.59) | GALR1GALR2SMN1; SMN2BCL6CYP2D6 | |
| SCHEMBL4832326 | 0.78 | BCL6 (0.59) | GALR1GALR2SMN1; SMN2BCL6CYP2D6 | |
| SCHEMBL4836523 | 0.78 | BCL6 (0.59) | GALR1GALR2SMN1; SMN2BCL6CYP2D6 | |
| SCHEMBL5555476 | 0.76 | GALR1 (0.45) | GALR1GALR2CDK1CDK4CCNB1 | |
| SCHEMBL5553594 | 0.76 | GALR1 (0.41) | GALR1GALR2CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-7173032-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GALR1 961/4885GALR2 668/4885CDK1 655/4885 |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | GALR1 1159/4885GALR2 712/4885CDK1 1388/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GALR1 961/4885GALR2 668/4885CDK1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.